Drugs / SH229
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT03748745 | Nov → Dec 2018 | — | Nanjing Sanhome Pharmaceutical, Co., Ltd. | Completed | No outcome recorded |
Also used as a comparator or background therapy in 1 trial
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT03588923 Comparator | Jul → Aug 2018 | hepatitis C virus infection | Nanjing Sanhome Pharmaceutical, Co., Ltd. | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | SH229 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03748745 ↗ |
| Route | Oral | “tablet, oral, 400 mg once daily for 3 days” NCT03588923 ↗ |